

Supplementary file.

Table S1. Results reported from specimens tested for routine viral load monitoring, for 21,833 specimens tested individually (2022), and for 12,296 specimens tested using pooled testing followed by individual testing for those from positive pools (Jul-Dec 2023), by result classification and quantitative result. (Specimens sent for reasons other than routine testing or for people <19 years of age were not included.)

			Routine HIV-1 viral load, results reported (2022)			Routine HIV-1 viral load, results reported, with pooled testing approach (Jul-Dec 2023)		
Result	HIV-1 viral load classification	copies/mL	Number (N)	Proportion (%)		Number (N)	Proportion (%)	
HIV-1 not detected*		0	15,334	70.2%	70.2%	11,228	90.6%	90.6%
HIV-1 detected	Suppressed	<40	3,074	14.1%	25.1%	227	1.8%	5.8%
		40-120	1,566	7.2%		190	1.5%	
		120-200	331	1.5%		84	0.7%	
		201-1,000	509	2.3%		218	1.8%	
HIV-1 detected	Unsuppressed	1,001-5,000	324	1.5%	4.7%	138	1.1%	3.6%
		5,001-10,000	113	0.5%		44	0.4%	
		10,001-100,000	356	1.6%		172	1.4%	
		>100,000	226	1.0%		95	0.8%	
Total			21,833			12,396		

*During pooled testing specimens from pools with results of HIV-1 not detected or detected below <40 copies/mL were reported as tested in a pool of 3, with a result of HIV-1 not detected or detected below the limit of detection of the assay

Figure S1. Passing-Bablok regression for pools of three for the Abbott HIV-1 RealTime assay. The dotted line is the line of equality, and the shaded area is the 95% confidence interval. Only specimens in pools of three with only one positive and two negative results were included, with results over the range 500 copies/mL to 5,000,000 copies/mL, which is the range over which the manufacturer reports that the assay was designed to achieve an inter-assay standard deviation of less than or equal to 0.25 copies/mL (214 specimens).

